Protocol PDX-010: A Phase 1, Open-Label Study of Pralatrexate With Vitamin B12 [cyanocobalamin] and Folic Acid Supplementation in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma.

Trial Profile

Protocol PDX-010: A Phase 1, Open-Label Study of Pralatrexate With Vitamin B12 [cyanocobalamin] and Folic Acid Supplementation in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma.

Completed
Phase of Trial: Phase I

Latest Information Update: 09 May 2013

At a glance

  • Drugs Pralatrexate (Primary) ; Cyanocobalamin; Folic acid
  • Indications Cutaneous T cell lymphoma
  • Focus Adverse reactions
  • Sponsors Allos Therapeutics; Spectrum Pharmaceuticals
  • Most Recent Events

    • 01 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Jan 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
    • 19 Jan 2012 Planned end date changed from 1 Jan 2012 to 1 Mar 2012 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top